Skip Navigation

AIDSInfo-at-a-glance

Issue No. 49 | November 24, 2010
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

NIAID Study Suggests Pre-Exposure Prophylaxis Reduces the Risk of HIV Infection Among MSM

“A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men. The findings, a major advance in HIV prevention research, come from a large international clinical trial published online Nov. 23 by the New England Journal of Medicine. The study, titled 'Chemoprophylaxis for HIV Prevention in Men,' found even higher rates of effectiveness, up to 72.8 percent, among those participants who adhered most closely to the daily drug regimen.

“‘We now have strong evidence that pre-exposure prophylaxis with an antiretroviral drug, a strategy widely referred to as PrEP, can reduce the risk of HIV acquisition among men who have sex with men, a segment of the population disproportionately affected by HIV/AIDS,’ says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. ‘Additional research is needed, but certainly this is an important finding that provides the basis for further investigating, developing and employing this prevention strategy, which has the potential to make a significant impact in the fight against HIV/AIDS.’ …

“The study participants were randomly assigned to receive either a daily antiretroviral tablet containing combination emtricitabine (FTC 200 milligrams) and tenofovir (TDF 300 milligrams), known by the brand name Truvada, or a placebo pill. … In addition, all participants were routinely counseled about safe sex practices and provided condoms and treatment for other sexually transmitted infections. …  

“Investigators will conduct a follow-on study in which all HIV-negative iPrEx participants will be offered the combination drug for 18 months. That study, which will begin in 2011, is designed to provide additional information about the drug’s long-term effectiveness and safety as well as participant risk behavior and pill-taking practices.”

More information is available:

“AIDSinfo – Top 10 in 2010” Video to be Released on World AIDS Day

On December 1, the HIV/AIDS community will observe World AIDS Day. The theme for the 2010 awareness day is “Stop AIDS. Keep the Promise – Universal Access and Human Rights.” Universal access to life-preserving HIV treatment, and to accurate and up-to-date information about that treatment, is a human rights issue.

AIDSinfo fulfills the 2010 World AIDS Day theme throughout the year by providing HIV/AIDS clinicians, researchers, and patients with the latest federally approved information on HIV research and treatment. To mark World AIDS Day, we are premiering “AIDSinfo – Top 10 in 2010,” a video showcasing our expanding services. The video underscores our commitment to “keep the promise” by extending our services to all who need HIV-related information and assistance.

Look for the “AIDSinfo – Top 10 in 2010” video in next week’s e-newsletter, on the National Institutes of Health (NIH OD) YouTube channel, and in the Health Island Auditorium in Second Life.

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Unsubscribe | Contact Us
Left footer corner image Left footer corner image